377,500 Shares in Avidity Biosciences, Inc. $RNA Purchased by Oddo BHF Asset Management Sas

Posted by Francis Steltz on Jun 16th, 2026

Oddo BHF Asset Management Sas acquired a new position in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 377,500 shares of the biotechnology company’s stock, valued at approximately $27,229,000. Avidity Biosciences accounts for approximately 1.0% of Oddo BHF Asset Management Sas’ portfolio, making the stock its 26th largest holding. Oddo BHF Asset Management Sas owned approximately 0.24% of Avidity Biosciences at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of RNA. AlphaQuest LLC increased its holdings in shares of Avidity Biosciences by 123.0% in the 3rd quarter. AlphaQuest LLC now owns 600 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 331 shares during the period. Los Angeles Capital Management LLC acquired a new position in Avidity Biosciences during the 4th quarter valued at about $34,000. Smartleaf Asset Management LLC increased its stake in Avidity Biosciences by 426.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 490 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 397 shares during the period. Allworth Financial LP increased its stake in Avidity Biosciences by 22.8% during the 3rd quarter. Allworth Financial LP now owns 856 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 159 shares during the period. Finally, Osaic Holdings Inc. increased its stake in Avidity Biosciences by 1,659.1% during the 2nd quarter. Osaic Holdings Inc. now owns 1,636 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,543 shares during the period.

Analyst Ratings Changes

Several equities analysts have commented on RNA shares. Wall Street Zen raised shares of Avidity Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, May 30th. Weiss Ratings cut shares of Avidity Biosciences from a “sell (d-)” rating to a “sell (e-)” rating in a research note on Friday, May 22nd. Wells Fargo & Company started coverage on shares of Avidity Biosciences in a research note on Wednesday, March 11th. They set an “overweight” rating on the stock. Leerink Partners started coverage on shares of Avidity Biosciences in a research note on Friday, May 15th. They set an “outperform” rating on the stock. Finally, HC Wainwright reissued a “neutral” rating on shares of Avidity Biosciences in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $70.29.

Get Our Latest Stock Report on RNA

Avidity Biosciences Price Performance

Avidity Biosciences stock opened at $12.75 on Tuesday. The firm’s 50 day simple moving average is $13.08 and its 200-day simple moving average is $41.19. The company has a market cap of $218.10 million, a P/E ratio of -2.57 and a beta of 0.93. Avidity Biosciences, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $16.77.

Avidity Biosciences (NASDAQ:RNA – Get Free Report) last released its earnings results on Thursday, May 14th. The biotechnology company reported ($0.97) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.08. The business had revenue of $19.64 million for the quarter, compared to the consensus estimate of $2.00 million. Avidity Biosciences had a negative net margin of 3,650.39% and a negative return on equity of 44.92%. On average, analysts expect that Avidity Biosciences, Inc. will post -2.89 EPS for the current fiscal year.

Avidity Biosciences Profile

(Free Report)

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.